One thing was clear from today’s presentation is that they didn’t shy away from talking about innovative trial design and new endpoints. I’d have thought they might compartmentalize Europe (EU + UK) vs US in terms of reporting given the uncertainty with FDA, but they didn’t. So they are cautiously optimistic that FDA will accept their BLA application with the new endpoints!
I don’t understand the harm in updating clinicaltrials website as soon as the publication is out. That’s one way to build credibility with the retail investors. The shorts have already done the damage!